Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance

被引：0

作者：

Xiong, Jin ^{[1
]}

Xia, Lei ^{[1
,2
,3
]}

机构：

[1] Chongqing Med Univ, Dept Canc Ctr, Affiliated Hosp 2, Chongqing, Peoples R China

[2] Peking Union Med Coll & Chinese Acad Med Sci, Tianjin Key Lab Radiat Med & Mol Nucl Med, Inst Radiat Med, Tianjin, Peoples R China

[3] Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Canc Inst & Hosp, Dept Radiat Oncol,Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

pleural effusion NGS; combination therapy; long-term survival; multiple-line ALK-TKI; case report; PLEURAL EFFUSION SUPERNATANT; NEEDLE TRACT IMPLANTATION; TUMOR-DERIVED DNA; CANCER; MULTICENTER; INHIBITOR;

D O I：

10.3389/fonc.2024.1419306

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutations and combining ALK-TKIs with angiogenic agents may improve survival. We report here one case with ALK-positive lung adenocarcinoma in which the patient achieved a prolonged progression-free survival (PFS) of 97 months after undergoing precise pleural effusion NGS and receiving combined bevacizumab treatment following multiple-line ALK-TKI resistance.

引用

页数：6

共 25 条

[1] Bevacizumab in advanced lung cancer: state of the art [J].

Assoun, Sandra ;

Brosseau, Solenn ;

Steinmetz, Christelle ;

Gounant, Valerie ;

Zalcman, Gerard .

FUTURE ONCOLOGY, 2017, 13 (28) :2515-2535

[2] Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens [J].

Bubendorf, Lukas ;

Lantuejoul, Sylvie ;

de langen, Adrianus J. ;

Thunnissen, Erik .

EUROPEAN RESPIRATORY REVIEW, 2017, 26 (144)

[3] Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas: Lessons learned from a 10-year experience [J].

Chang, Samuel ;

Kim, Seong Hyun ;

Lim, Hyo K. ;

Kim, Seung Hoon ;

Lee, Won Jae ;

Choi, Dongil ;

Kim, Young-Sun ;

Rhim, Hyunchul .

KOREAN JOURNAL OF RADIOLOGY, 2008, 9 (03) :268-274

[4] Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression [J].

Choudhury, Noura J. ;

Young, Robert J. ;

Sellitti, Matthew ;

Miller, Alexandra ;

Drilon, Alexander .

JCO PRECISION ONCOLOGY, 2020, 4 :1333-1338

[5] Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers [J].

Drilon, Alexander ;

Lin, Jessica J. ;

Filleron, Thomas ;

Ni, Ai ;

Milia, Julie ;

Bergagnini, Isabella ;

Hatzoglou, Vaios ;

Velcheti, Vamsidhar ;

Offin, Michael ;

Li, Bob ;

Carbone, David P. ;

Besse, Benjamin ;

Mok, Tony ;

Awad, Mark M. ;

Wolf, Jurgen ;

Owen, Dwight ;

Camidge, D. Ross ;

Riely, Gregory J. ;

Peled, Nir ;

Kris, Mark G. ;

Mazieres, Julien ;

Gainor, Justin F. ;

Gautschi, Oliver .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :1595-1601

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [J].

Gainor, Justin F. ;

Dardaei, Leila ;

Yoda, Satoshi ;

Friboulet, Luc ;

Leshchiner, Ignaty ;

Katayama, Ryohei ;

Dagogo-Jack, Ibiayi ;

Gadgeel, Shirish ;

Schultz, Katherine ;

Singh, Manrose ;

Chin, Emily ;

Parks, Melissa ;

Lee, Dana ;

DiCecca, Richard H. ;

Lockerman, Elizabeth ;

Huynh, Tiffany ;

Logan, Jennifer ;

Ritterhouse, Lauren L. ;

Le, Long P. ;

Muniappan, Ashok ;

Digumarthy, Subba ;

Channick, Colleen ;

Keyes, Colleen ;

Getz, Gad ;

Dias-Santagata, Dora ;

Heist, Rebecca S. ;

Lennerz, Jochen ;

Sequist, Lecia V. ;

Benes, Cyril H. ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CANCER DISCOVERY, 2016, 6 (10) :1118-1133

[8] A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan [J].

Goto, Yasushi ;

Kenmotsu, Hirotsugu ;

Tamiya, Motohiro ;

Murakami, Shuji ;

Kurata, Takayasu ;

Yanagitani, Noriko ;

Taniguchi, Hirokazu ;

Kuyama, Shoichi ;

Shimizu, Junichi ;

Yokoyama, Toshihide ;

Shimada, Naoko ;

Maeda, Tadashi ;

Tamiya, Akihiro ;

Uchiyama, Ayumi ;

Imaizumi, Kazuyoshi ;

Takahama, Takayuki ;

Kato, Terufumi ;

Hayashi, Hidetoshi ;

Shiraiwa, Naoko ;

Toyoizumi, Shigeyuki ;

Kikkawa, Hironori ;

Thomaidou, Despina ;

Nishio, Makoto .

JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05)

[9] Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease [J].

Hiley, Crispin T. ;

Le Quesne, John ;

Santis, George ;

Sharpe, Rowena ;

de Castro, David Gonzalez ;

Middleton, Gary ;

Swanton, Charles .

LANCET, 2016, 388 (10048) :1002-1011

[10] A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer [J].

Jin, Shidai ;

Zhou, Chengzhi ;

Hou, Xue ;

Fan, Zaiwen ;

Zhao, Jun ;

Ai, Xinghao ;

Chu, Yuxing ;

Chen, Rongrong ;

Guo, Renhua ;

Chen, Likun .

TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) :1507-1515

← 1 2 3 →